-
Inconsistent criteria used in ASCO 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. JCO 26(12):2058-9, 2008
-
Comparison of prognostic gene expression signatures forbreast cancer. BMC Genomics 9:394, 2008
-
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Research Treatment Jul 27 2008 [Epub ahead of print]
-
Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank. On behalf of the Blood, FFPE, and Fresh/Frozen Tissue Working Groups of the NCI Cooperative Group Banking Committee, Breast International Group, and the North American breast cancer Cooperative Groups. JCO in press
-
New tools for assessing breast cancer recurrence. Cancer Treat Res 141:99-118, 2008
-
New tools for assessing breast cancer recurrence. In: Advances in Breast Cancer Management 2nd Edition, Eds Gradishar W and Wood W; Cancer Treatment and Research, Series Editor Steven Rosen; Springer, USA,
99-118, 2008
-
Personalized medicine by the use of microarray gene expression profiling. In: Pharmacogenetics of Breast Cancer: towards the Individualization of Therapy. Translational Medecine Series 7. Editor Leyland-Jones B; Informa Healthcare USA, Inc, 123-134, 2008
-
Clinical application of the 70-gene profile (Mammaprint™): The MINDACT trial. JCO 26(5): 729–735, 2008
-
The MINDACT trial: the first prospective clinical validation of a genomic tool. Molecular Oncology 1(3), 246-251, 2007.
-
Robust interlaboratory reproducibility of gene expression signature measurement consistent with the needs of a new generation of diagnostic tool. BMC Genomics, 8: 148, 2007.
-
Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-centre independent validation series. Clinical Cancer Research - June 2007.
-
Individualization of therapy using Mammaprint®?: from development to the MINDACT trial. Cancer Genomics and Proteomics, 4: 147-156, July 2007.
-
Multi-centre independent validation of a 70-gene prognostic signature for women with node negative breast cancer, Journal of the National Cancer Institute - September 2006.
-
Prospective evaluation of a gene signature as a new prognostic tool in early stage breast cancer: background and challenges in the design of MINDACT (Microarray In Node negative Disease May Avoid Chemotherapy Trial) Nature Clinical Practice Oncology - October 2006.
-
Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are the results still outperforming the clinical-pathological criteria? Breast Cancer Research and Treatment - 2004.
-
Gene expression profiling predicts clinical outcome of breast cancer. Nature Clinical Practice Oncology , 415: 530-536, 2002.
-
A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medecine - 347: 1999-2009, 2002.